CD30-directed antibody-drug conjugate
Showing 1 - 25 of >10,000
Light Chain (AL) Amyloidosis Trial (STI-6129)
Not yet recruiting
- Light Chain (AL) Amyloidosis
- STI-6129
- (no location specified)
Jan 11, 2023
Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Seattle (drug, other,
Recruiting
- Recurrent Hodgkin Lymphoma
- +3 more
- Brentuximab Vedotin
- +2 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Oct 4, 2022
Relapsed or Refractory Multiple Myeloma Trial in Beijing, Guangzhou, Hangzhou (STI-6129)
Not yet recruiting
- Relapsed or Refractory Multiple Myeloma
- STI-6129
-
Beijing, Beijing, China
- +3 more
Jan 9, 2023
Advanced Solid Tumor Trial in New York (STI-6129)
Not yet recruiting
- Advanced Solid Tumor
- STI-6129
-
New York, New YorkColumbia University Medical Center
Jan 26, 2023
Light Chain (AL) Amyloidosis Trial in New York (STI-6129)
Recruiting
- Light Chain (AL) Amyloidosis
- STI-6129
-
Duarte, California
- +3 more
Jan 12, 2023
Recurrent Classic Hodgkin Lymphoma Trial in Duarte (Brentuximab Vedotin, Nivolumab)
Recruiting
- Recurrent Classic Hodgkin Lymphoma
- Brentuximab Vedotin
- Nivolumab
-
Duarte, CaliforniaCity of Hope Medical Center
Feb 16, 2022
Multiple Myeloma Trial in Canton (STI-6129)
Recruiting
- Multiple Myeloma
- STI-6129
-
Canton, OhioGabrail Cancer Center
Jun 29, 2022
CD30-Positive Neoplastic Cells Present, Malignant Mesothelioma Trial in Houston (Brentuximab Vedotin, Laboratory Biomarker
Recruiting
- CD30-Positive Neoplastic Cells Present
- Malignant Mesothelioma
- Brentuximab Vedotin
- Laboratory Biomarker Analysis
-
Houston, TexasM D Anderson Cancer Center
Jan 3, 2022
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Duarte (Brentuximab Vedotin, Cyclosporine, Pharmacokinetic
Active, not recruiting
- Recurrent Hodgkin Lymphoma
- Refractory Hodgkin Lymphoma
- Brentuximab Vedotin
- +4 more
-
Duarte, CaliforniaCity of Hope Medical Center
Feb 17, 2022
HIV Infection, HIV-associated Hodgkin Lymphoma, Stage III Adult Hodgkin Lymphoma Trial in France (brentuximab vedotin,
Active, not recruiting
- HIV Infection
- +3 more
- brentuximab vedotin
- +3 more
-
Clamart, France
- +5 more
Aug 11, 2022
Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma Trial in Sacramento (Bendamustine Hydrochloride, Brentuximab
Recruiting
- Recurrent Follicular Lymphoma
- Refractory Follicular Lymphoma
- Bendamustine Hydrochloride
- Brentuximab Vedotin
-
Sacramento, CaliforniaUniversity of California Davis Comprehensive Cancer Center
Dec 17, 2021
Advanced Solid Tumors Trial in Canada, United States (LCB84, Anti-PD-1 mAb)
Not yet recruiting
- Advanced Solid Tumors
- LCB84
- Anti-PD-1 monoclonal antibody
-
Los Angeles, California
- +6 more
Jul 4, 2023
Solid Tumor Trial in United States (OBT076, a CD205-directed antibody-drug conjugate)
Recruiting
- Solid Tumor
- OBT076, a CD205-directed antibody-drug conjugate
-
Los Angeles, California
- +5 more
Jan 10, 2022
Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Recurrent Follicular T-Cell
Recruiting
- Recurrent Angioimmunoblastic T-Cell Lymphoma
- +13 more
- Brentuximab Vedotin
- Pembrolizumab
-
Chicago, IllinoisNorthwestern University
Jun 15, 2022
Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma Trial (procedure, drug, biological, radiation, other)
Not yet recruiting
- Recurrent Classic Hodgkin Lymphoma
- Refractory Classic Hodgkin Lymphoma
- Autologous Hematopoietic Stem Cell Transplantation
- +13 more
- (no location specified)
Feb 2, 2023
Classic Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in United States (drug, other,
Active, not recruiting
- Classic Hodgkin Lymphoma
- +2 more
- Brentuximab Vedotin
- +2 more
-
Duarte, California
- +5 more
Mar 17, 2022
Metastatic Castration-resistant Prostate Cancer, Prostate Cancer Trial in San Francisco (FOR46, Enzalutamide, Pegfilgrastim)
Recruiting
- Metastatic Castration-resistant Prostate Cancer
- Prostate Cancer
- FOR46
- +2 more
-
San Francisco, CaliforniaUniversity of California, San Francisco
Jun 1, 2022
Diffuse Cutaneous Systemic Sclerosis Trial in London (Brentuximab Vedotin)
Recruiting
- Diffuse Cutaneous Systemic Sclerosis
- Brentuximab Vedotin
-
London, Ontario, CanadaRheumatology Clinic, St. Joseph's Health Care
Feb 3, 2022
Ann Arbor Stage IB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma Trial in United
Active, not recruiting
- Ann Arbor Stage IB Hodgkin Lymphoma
- +10 more
- Brentuximab Vedotin
- Nivolumab
-
Palo Alto, California
- +8 more
Jul 20, 2022
Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage II Primary Mediastinal (Thymic) Large
Recruiting
- Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma
- +3 more
- Brentuximab Vedotin
- +6 more
-
Houston, TexasM D Anderson Cancer Center
Feb 10, 2022
DLBCL, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial (biological, procedure, drug,
Not yet recruiting
- Diffuse Large B-Cell Lymphoma
- +6 more
- Axicabtagene Ciloleucel
- +10 more
- (no location specified)
Jan 13, 2023
Multiple Myeloma Trial in United States (hLL1-DOX (the doxorubicin conjugate of milatuzumab))
Terminated
- Multiple Myeloma
- hLL1-DOX (the doxorubicin conjugate of milatuzumab)
-
Orlando, Florida
- +4 more
Aug 12, 2021
DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to DLBCL Trial
Not yet recruiting
- Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- +2 more
- Biospecimen Collection
- +5 more
- (no location specified)
Sep 5, 2023
AIDS-Related Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma Trial in France, United
Active, not recruiting
- AIDS-Related Hodgkin Lymphoma
- +11 more
- Brentuximab Vedotin
- +4 more
-
La Jolla, California
- +27 more
Jul 27, 2022